Compare
Kyverna Therapeutics, Inc. vs Alector, Inc. vs X4 Pharmaceuticals, Inc vs LENZ Therapeutics, Inc.
| Latest fiscal year | Kyverna Therapeutics, Inc. KYTX | Alector, Inc. ALEC | X4 Pharmaceuticals, Inc XFOR | LENZ Therapeutics, Inc. LENZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $21.05M | $35.11M | $19.09M |
| Revenue growth (YoY) | n/a | -79.1% | n/m | n/a |
| Gross margin | n/a | n/a | 83.6% (computed) | n/a |
| Operating margin | n/a | -741.3% | -247.4% | -477.5% |
| Net margin | n/a | -679.2% | -225.6% | -430.3% |
| Net income | -$161.31M | -$142.93M | -$79.20M | -$82.13M |
| EPS (Diluted) | -$3.64 | -$1.39 | -$1.87 | -$2.85 |
| Operating cash flow | -$153.71M | -$184.03M | -$85.62M | -$69.17M |
| Free cash flow | -$153.72M | -$184.07M | -$85.62M | -$70.00M |
| Cash & equivalents | $124.09M | $65.80M | $217.05M | $25.18M |
| Total assets | $293.83M | $293.24M | $290.46M | $305.88M |
| Total liabilities | $61.55M | $262.59M | $104.17M | $21.54M |
| Shareholders' equity | $232.28M | $30.65M | $186.29M | $284.34M |
| Return on year-end equity | -69.4% | -466.3% | -42.5% | -28.9% |
| Shares outstanding | 60.39M | 110.36M | 90.91M | 31.34M |
Revenue, most recent five fiscal years
| Fiscal year | Kyverna Therapeutics, Inc. | Alector, Inc. | X4 Pharmaceuticals, Inc | LENZ Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $21.05M Ended 2025-12-31 | $35.11M Ended 2025-12-31 | $19.09M Ended 2025-12-31 |
| 1 year earlier | n/a | $100.56M Ended 2024-12-31 | $2.56M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $97.06M Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $133.62M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $207.09M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a |